At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
Displaying 541–550 of 599 results.
-
The purpose of this study is to find the highest dose of the investigational drug PF-07799933 that can be given alone and in combination with binimetinib or cetuximab in people with advanced solid tumors that have continued to grow despite treatment and contain a mutation in the BRAF gene. A mutated BRAF gene makes a protein that sends signals to cancer cells to grow and divide. While some anti-cancer drugs only work for certain BRAF mutations, the investigational drug PF-07799933 may target all types of BRAF mutant proteins, blocking them from sending these signals and causing cancer cells to die.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Researchers are assessing a new way of giving isatuximab with carfilzomib and dexamethasone in people with multiple myeloma. Isatuximab is injected under the skin using a wearable device attached to the skin of the stomach area. Carfilzomib will be given intravenously (by vein). Dexamethasone can be taken orally (by mouth) or intravenously. 
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Researchers want to see how well reparixin works against myelofibrosis. This disease is a rare bone marrow cancer that disrupts your body's normal blood cell production. 
-
Chemotherapy for lymphoma can cause side effects, especially in people age 65 and older and those with other health problems. Researchers want to see if adding the immunotherapy drugs glofitamab, polatuzumab, and obinutuzumab to treatment can reduce the amount of chemotherapy needed. The people in this study have diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), or transformed lymphoma. Their cancer has not yet been treated.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Myelofibrosis is a rare disease known as a myeloproliferative neoplasm. The bone marrow becomes scarred and cannot make enough blood cells, leading to anemia. Anemia is low number of red blood cells, causing tiredness and shortness of breath. Some people with myelofibrosis need regular transfusions of blood. In this study, researchers want to see if momelotinib given with luspatercept reduces the need for blood transfusions in these patients. Momelotinib works by blocking two proteins called JAK and ACVR1. When JAK proteins send too many signals, the body makes the wrong amount of blood cells. By blocking JAK, momelotinib may help your body make the right amount of blood cells. By targeting ACVR1, momelotinib may fight anemia. Momelotinib is taken orally (by mouth).  By improving red blood cell development, luspatercept may reduce the need for blood transfusions in people with transfusion-dependent myelofibrosis. Luspatercept is given by an injection under the skin. 
-
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread). The benefits of hormone treatments do not last, however. Over time, many prostate cancers keep growing even with hormonal therapies. These are called metastatic castration-resistant prostate cancers (mCRPC).
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.